» Authors » Alberto Jimenez Morales

Alberto Jimenez Morales

Explore the profile of Alberto Jimenez Morales including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 132
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Marquez Pete N, Perez Ramirez C, Maldonado Montoro M, Martinez Martinez F, Fernandez-Llimos F, Sanchez Pozo A, et al.
Arch Med Sci . 2024 Dec; 20(5):1529-1537. PMID: 39649257
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology which causes progressive deterioration of the joints, leading to severe pain and functional disability. Vitamin D and...
2.
Roldan A, Alarcon-Payer C, Sanchez Suarez M, Morales A
Anticancer Drugs . 2024 Nov; 36(2):154-156. PMID: 39589257
This case report highlights sorafenib as maintenance therapy postallogeneic hematopoietic stem cell transplantation (allo-HSCT) in a young patient with acute myeloid leukemia (AML) with FMS-like tirosine kinase-3 (FLT3)-internal tandem duplication...
3.
Roldan A, Alarcon-Payer C, Sanchez Suarez M, Morales A
Anticancer Drugs . 2024 Jul; 35(9):872-874. PMID: 39008456
We present a case of a patient diagnosed with FLT3 mut+ acute myeloid leukemia with FLT3 and NMP1 mutations who did not respond to standard induction and consolidation treatment with...
4.
Sanchez Suarez M, Roldan A, Cuenca M, Morales A
Farm Hosp . 2024 Jun; 48(5):T230-T233. PMID: 38825444
Objective: To determine the prevalence of PIMDINAC criteria and to implement pharmacological interventions in a population with multiple sclerosis over 55 years of age. Methods: Retrospective, observational, open-label study, including...
5.
Sanchez Suarez M, Roldan A, Alarcon-Payer C, Rodriguez-Gil M, Poquet-Jornet J, Puerta Puerta J, et al.
Pharmaceutics . 2024 Jan; 16(1). PMID: 38258066
Chronic lymphocytic leukemia is a lymphoproliferative disorder marked by the expansion of monoclonal, mature CD5+CD23+ B cells in peripheral blood, secondary lymphoid tissues, and bone marrow. The disease exhibits significant...
6.
Roldan A, Sanchez Suarez M, Alarcon-Payer C, Morales A, Puerta Puerta J
Pharmaceutics . 2023 May; 15(5). PMID: 37242605
The therapeutic approach to chronic myeloid leukaemia (CML) has changed in recent years. As a result, a high percentage of current patients in the chronic phase of the disease almost...
7.
Cura Y, Perez-Ramirez C, Sanchez-Martin A, Membrive-Jimenez C, Valverde-Merino M, Gonzalez-Flores E, et al.
Cancers (Basel) . 2023 Mar; 15(6). PMID: 36980706
The aim of this systematic review was to provide a comprehensive overview of the literature published in the last decade on the association of single-nucleotide polymorphisms in genes involved in...
8.
Pineda Lancheros L, Rojo Tolosa S, Galvez Navas J, Martinez Martinez F, Martin A, Morales A, et al.
Nutrients . 2022 Nov; 14(21). PMID: 36364930
The pathogenesis of non-small-cell lung cancer (NSCLC) is complex, since many risk factors have been identified. Recent research indicates that polymorphisms in the metabolic pathway of vitamin D may be...
9.
Alarcon-Payer C, Sanchez Suarez M, Roldan A, Puerta Puerta J, Morales A
J Pers Med . 2022 Oct; 12(10). PMID: 36294746
Most malignant hematological diseases are generally a consequence of acquired mutations or rearrangements in cell replication processes. Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease that results...
10.
Gonzalez Rojo P, Perez Ramirez C, Galvez Navas J, Pineda Lancheros L, Rojo Tolosa S, Ramirez Tortosa M, et al.
Int J Mol Sci . 2022 Aug; 23(15). PMID: 35955825
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels. In addition to environmental risk factors, genetic predisposition increases the risk; this includes alterations in the...